Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bjoern Moosmann

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Mass Spectrometry : JMS|August 19, 2016
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolamBjoern Moosmann, Philippe Bisel, Florian Franz, et al.
Forensic Science International|January 24, 2012
Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography systemBjoern Moosmann, Stefan Kneisel, Ulrich Girreser, et al.
Toxicology and Applied Pharmacology|April 2, 2014
Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8Verena J Koller, Volker Auwärter, Tamara Grummt, et al.
Drug Testing and Analysis|July 30, 2014
Cannabinoid findings in children hair - what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ9-tetrahydrocannabinolic acid A concentrationsBjoern Moosmann, Nadine Roth, Martin Hastedt, et al.
Journal of Mass Spectrometry : JMS|November 22, 2013
Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokineticsBjoern Moosmann, Laura M Huppertz, Melanie Hutter, et al.
Drug Testing and Analysis|December 23, 2018
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)Bjoern Moosmann, Philippe Bisel, Folker Westphal, et al.
Analytical and Bioanalytical Chemistry|March 29, 2013
LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windowsStefan Kneisel, Michael Speck, Bjoern Moosmann, et al.
Drug Testing and Analysis|February 19, 2016
In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stabilityFlorian Franz, Verena Angerer, Simon D Brandt, et al.
Drug Testing and Analysis|May 5, 2018
Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samplesLukas Mogler, Florian Franz, Maurice Wilde, et al.
Drug Testing and Analysis|April 4, 2017
Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samplesLukas Mogler, Florian Franz, Daniel Rentsch, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Mass Spectrometry : JMS|August 19, 2016
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolamBjoern Moosmann, Philippe Bisel, Florian Franz, et al.
Forensic Science International|January 24, 2012
Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography systemBjoern Moosmann, Stefan Kneisel, Ulrich Girreser, et al.
Toxicology and Applied Pharmacology|April 2, 2014
Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8Verena J Koller, Volker Auwärter, Tamara Grummt, et al.
Drug Testing and Analysis|July 30, 2014
Cannabinoid findings in children hair - what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ9-tetrahydrocannabinolic acid A concentrationsBjoern Moosmann, Nadine Roth, Martin Hastedt, et al.
Journal of Mass Spectrometry : JMS|November 22, 2013
Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokineticsBjoern Moosmann, Laura M Huppertz, Melanie Hutter, et al.
Drug Testing and Analysis|December 23, 2018
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)Bjoern Moosmann, Philippe Bisel, Folker Westphal, et al.
Analytical and Bioanalytical Chemistry|March 29, 2013
LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windowsStefan Kneisel, Michael Speck, Bjoern Moosmann, et al.
Drug Testing and Analysis|February 19, 2016
In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stabilityFlorian Franz, Verena Angerer, Simon D Brandt, et al.
Drug Testing and Analysis|May 5, 2018
Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samplesLukas Mogler, Florian Franz, Maurice Wilde, et al.
Drug Testing and Analysis|April 4, 2017
Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samplesLukas Mogler, Florian Franz, Daniel Rentsch, et al.
Pageof 4